PCI Biotech Holding ASA (OSL: PCIB)

Market Cap	49.72M
Revenue (ttm)	6.00M
Net Income (ttm)	-15.91M
Shares Out	37.33M
EPS (ttm)	-0.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	146,972
Open	1.262
Previous Close	1.250
Day's Range	1.262 - 1.598
52-Week Range	1.100 - 3.500
Beta	1.73
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 27, 2025

About PCI Biotech Holding ASA

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company’s technology platform consists of a proprietary small molecule photosensitiser (fimaporfin) and a light source; and develops photochemical internalisation (PCI), inducing light-triggered intracellular release for various therapeutic modalities, as well as photochemical lysis (PCL) comprising light-triggered cell lysis...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 6
• Stock Exchange: Oslo Børs
• Ticker Symbol: PCIB

Financial Performance

In 2023, PCI Biotech Holding ASA's revenue was 2.99 million, a decrease of -37.05% compared to the previous year's 4.75 million. Losses were -20.32 million, -63.13% less than in 2022.